Financial Data and Key Metrics Changes - Research and development expenses decreased to $16.5 million for Q4 2025 from $20.3 million in Q4 2024, primarily due to strategic reprioritization and reduced costs associated with the pausing of the Revitalize-1 study [24] - SG&A expenses increased to $6.8 million for Q4 2025 from $4.9 million in Q4 2024, mainly due to underwriter's commissions related to financing [24] - The net loss for Q4 2025 was $43.7 million compared to $25 million in Q4 2024, with a significant portion of the increase attributed to a non-cash accounting change [25] - Adjusted EBITDA improved to -$21.2 million for Q4 2025 from -$22.1 million in Q4 2024, reflecting a decrease in operating expenses [25] - As of December 31, 2025, the company had approximately $81.5 million in cash and cash equivalents, expected to fund operations into early 2027 [25][26] Business Line Data and Key Metrics Changes - Revita is positioned as a solution for maintaining weight loss after GLP-1 therapy discontinuation, with a focus on a specific patient population that shows a strong treatment effect [4][20] - The pivotal study has enrolled over 300 participants across more than 30 sites, making it the largest sham-controlled GI endoscopy pivotal trial conducted [18] Market Data and Key Metrics Changes - The anticipated population on GLP-1 drugs is projected to exceed 30 million in the coming years, with over 50% expected to lose more than 17.5% of their total body weight [20] - The payer landscape is evolving, with expanded Medicare coverage of GLP-1s increasing the addressable patient population while also intensifying economic pressures on payers [20] Company Strategy and Development Direction - The company aims to submit a de novo classification request for Revita by late Q4 2026, with favorable FDA feedback received on the safety profile [19][20] - Revita is the first FDA breakthrough device designed for post GLP-1 weight maintenance, addressing a significant unmet need in the market [20] - The company plans to file a Category III CPT code application in summer 2026, with expectations for it to be effective by summer 2027 [21][62] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical signal of Revita, highlighting a strong dose-response relationship and a clear target population for treatment [28] - The pivotal study is designed to succeed with strong powering and an optimized cohort of patients, aiming for a positive outcome [28] - The company is committed to operating within its existing capital envelope until pivotal data is available, signaling alignment with shareholders [27][28] Other Important Information - The Rejuva program, targeting long-term metabolic remission from a single dose, is advancing with clinical trial applications submitted in the EU and Australia [22] - The company anticipates several key milestones in 2026, including pivotal data readouts and regulatory feedback [23] Q&A Session Summary Question: How is the ablation length determined? - Ablation length is calculated based on the total amount of duodenum ablated during the procedure, with a target minimum of 16 cm established for future procedures [31][33] Question: Does this impact how doctors will be trained in the future? - Physicians are trained to perform at least 10 cm of ablation, with the expectation that they can consistently achieve greater than 14 cm based on the data [34] Question: What is the role of efficacy in the de novo submission? - The de novo pathway determination is primarily a safety consideration, with efficacy being assessed as reasonable assurance of safety and effectiveness [39] Question: How long does it take to train physicians for the procedure? - Training takes less than three to four cases for physicians to perform adequate ablations, with consistency improving as they gain experience [56] Question: Will there be further analysis by length for the REMAIN-1 midpoint cohort? - Yes, further analysis by length will be provided in the upcoming data readouts [60] Question: What is the timeline for the CPT code filing? - The company plans to file for a Category III CPT code in June 2026, with an expected effective date in summer 2027 [62]

Financial Data and Key Metrics Changes - Research and development expenses decreased to $16.5 million for Q4 2025 from $20.3 million in Q4 2024, primarily due to strategic reprioritization and reduced costs associated with the pausing of the Revitalize One study [24] - SG&A expenses increased to $6.8 million for Q4 2025 from $4.9 million in Q4 2024, mainly due to underwriter's commissions from financing [24] - The net loss for Q4 2025 was $43.7 million compared to $25 million in Q4 2024, with a significant portion of the increase attributed to a non-cash accounting change [25] - Adjusted EBITDA improved to negative $21.2 million for Q4 2025 from negative $22.1 million in Q4 2024, reflecting a decrease in operating expenses [25] - As of December 31, 2025, the company had approximately $81.5 million in cash and cash equivalents, expected to fund operations into early 2027 [25][26] Business Line Data and Key Metrics Changes - Revita, the lead asset, is positioned as a solution for maintaining weight loss after GLP-1 therapy discontinuation, with a focus on a pivotal study designed to validate its efficacy [4][5] - The pivotal study has enrolled over 300 participants across more than 30 sites, making it the largest sham-controlled GI endoscopy pivotal trial conducted [18] Market Data and Key Metrics Changes - The anticipated population on GLP-1 drugs is projected to exceed 30 million users in the coming years, with over 50% expected to lose more than 17.5% of their total body weight [20] - The payer landscape is evolving, with expanded Medicare coverage of GLP-1s increasing the addressable patient population and intensifying economic pressures on payers [20] Company Strategy and Development Direction - The company aims to submit a de novo classification request for Revita by late Q4 2026, with favorable FDA feedback received on its safety profile [19] - Revita is positioned as the first FDA breakthrough device designed for post GLP-1 weight maintenance, addressing a significant unmet need in the market [20] - The company plans to file a Category III CPT code application in summer 2026, with expectations for effective reimbursement by summer 2027 [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical signal of Revita, highlighting a strong dose-response relationship and a well-structured pivotal study [28] - The company is committed to operating within its existing capital envelope without planned incremental capital raises before pivotal data is available [27][28] - Management anticipates delivering top-line six-month primary endpoint data in early Q4 2026, which is considered a critical milestone for the company [24][28] Other Important Information - The Rejuva program, targeting long-term metabolic remission from a single dose, is advancing with clinical trial applications submitted in the EU and Australia [22] - The company is preparing for a potential commercial launch of Revita, with a clear and validated pathway for reimbursement [21][22] Q&A Session Summary Question: How is the ablation length determined? - Ablation length is calculated based on the total amount of duodenum ablated during the procedure, with a target minimum of 16 centimeters established for future studies [31][33] Question: Does this impact physician training for ablation length? - Physicians were advised to aim for at least 10 centimeters of ablation, with training allowing them to consistently achieve greater than 14 centimeters [34] Question: What is the role of efficacy in the de novo submission? - The de novo pathway primarily considers safety, with efficacy being a secondary factor compared to PMA submissions [39] Question: Is 16 centimeters of ablation readily achievable in the average patient? - In the pivotal cohort, the mean and median ablation length exceeded 16 centimeters, which is considered achievable by trained investigators [41] Question: How long does it take to train physicians for the procedure? - Training typically requires less than 3-4 cases for physicians to perform adequate ablations [56]

Financial Data and Key Metrics Changes - Research and development expenses decreased to $16.5 million for Q4 2025 from $20.3 million in Q4 2024, primarily due to strategic reprioritization and lower personnel-related costs [24] - SG&A expenses increased to $6.8 million for Q4 2025 from $4.9 million in Q4 2024, mainly due to underwriter's commissions from financing [24] - The net loss for Q4 2025 was $43.7 million compared to $25 million in Q4 2024, with a significant portion of the increase attributed to a non-cash accounting change [25] - Adjusted EBITDA improved to negative $21.2 million for Q4 2025 from negative $22.1 million in Q4 2024, reflecting a decrease in operating expenses [25] - As of December 31, 2025, the company had approximately $81.5 million in cash and cash equivalents, expected to fund operations into early 2027 [25] Business Line Data and Key Metrics Changes - Revita, the lead asset, is positioned as a solution for maintaining weight loss after GLP-1 therapy discontinuation, with a focus on a pivotal study designed to validate its efficacy [4][5] - The REMAIN-1 pivotal study has enrolled over 300 participants across more than 30 sites, making it the largest sham-controlled GI endoscopy pivotal trial conducted [17] Market Data and Key Metrics Changes - The anticipated filing via the de novo pathway is expected to coincide with a growing population of over 30 million users of GLP-1 drugs, with more than 50% likely to lose over 17.5% of their total body weight [19] - The payer landscape is evolving, with expanded Medicare coverage for GLP-1s, increasing the addressable patient population and creating economic pressure on payers [20] Company Strategy and Development Direction - The company aims to submit a de novo classification request by late Q4 2026, with favorable FDA feedback received on its safety profile [18] - Revita is positioned as the first FDA breakthrough device designed for post GLP-1 weight maintenance, addressing a significant unmet need in the market [20] - The Rejuva program is advancing separately, targeting long-term metabolic remission from a single dose, with clinical trial applications submitted in the EU and Australia [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical signal of Revita, highlighting a strong dose-response relationship and a well-structured pivotal study [27] - The company is committed to operating within its existing capital envelope without planned incremental capital raises before pivotal data is available [27] - Management anticipates delivering top-line six-month primary endpoint data in early Q4 2026, which is considered a critical milestone for the company [24][27] Other Important Information - The company plans to file a Category III CPT code application in summer 2026, with expectations for it to take effect in summer 2027 [20] - Transitional Pass-Through Payment via CMS is expected to provide a mechanism to cover the cost of the Revita device, ensuring hospitals can maintain a positive contribution margin [21] Q&A Session Summary Question: How is the ablation length determined? - Ablation length is determined during the procedure, with a target minimum of 16 centimeters established based on previous studies [31][33] Question: Does this impact how doctors will be trained in the future regarding ablation length? - Physicians were trained to perform at least 10 centimeters of ablation, with the expectation that they can consistently achieve greater than 14 centimeters based on the data [34] Question: What role does efficacy play in the de novo submission? - The de novo pathway determination is primarily a safety consideration, with efficacy being assessed under a reasonable assurance of safety and effectiveness [39] Question: How long does it take to train physicians for the procedure? - Training takes less than 3-4 cases to ensure physicians can perform adequate ablation [57] Question: Will there be further analysis by length for the one-year REMAIN midpoint cohort? - Yes, further analysis by length will be provided [62]

Core Insights - Fractyl Health, Inc. has completed randomization in the REMAIN-1 Pivotal Cohort, with topline 6-month data expected in early Q4 2026, and received favorable FDA feedback on its De Novo classification request, with submission anticipated in late Q4 2026 [1][2][10] Clinical Developments - New post-hoc analyses from the REMAIN-1 Midpoint Cohort show a statistically significant ablation-length (dose)-dependent treatment effect on post-GLP-1 weight maintenance at 6 months, reinforcing confidence in the REMAIN-1 Pivotal Cohort design [2][4][5] - Patients with greater GLP-1-induced weight loss prior to randomization exhibited larger sham-adjusted treatment effects at 6 months, with effect size increasing over time [1][3][5] Financial Performance - For Q4 2025, Fractyl reported a net loss of $43.7 million, compared to $25.0 million for the same period in 2024, primarily due to a non-cash accounting change in fair value related to warrant liabilities [19][31] - Research and development expenses were $16.5 million for Q4 2025, down from $20.3 million in Q4 2024, attributed to strategic reprioritization [19][29] - As of December 31, 2025, the company had approximately $81.5 million in cash and cash equivalents, which is expected to fund operations into early 2027 [19][28] Regulatory Strategy - The FDA has acknowledged the safety profile of the Revita DMR System as consistent with a Class II device classification, with final determinations pending a complete safety dataset review [10][17] - The company is advancing toward multiple anticipated clinical and regulatory milestones, including pivotal readout and potential U.S. regulatory submission [9][10] Market Context - Approximately 30 million patients are projected to be on GLP-1s by 2035, with many facing discontinuation and significant weight regain, highlighting the potential market for Fractyl's procedural therapy for post-GLP-1 weight maintenance [3][4]

Core Insights - Fractyl Health, Inc. (NASDAQ:GUTS) is recognized as one of the best high-volume penny stocks to buy, with a maintained Buy rating and an $8 price target from H.C. Wainwright despite a recent sharp selloff [1][5] - The company's stock experienced a 65% decline following the January data release, attributed to concerns over statistical significance and weight-regain trends [1] - H.C. Wainwright suggests that the results are consistent with previous Revita data and highlights a potential pivotal readout in Q4 that could enhance Revita's positioning as a treatment option after GLP-1 therapy discontinuation [1] Company Developments - On February 26, 2026, Fractyl Health announced the completion of participant randomization in its REMAIN-1 pivotal cohort, a double-blind study aimed at evaluating Revita for weight maintenance after GLP-1 discontinuation [2] - CEO Harith Rajagopalan emphasized the importance of this milestone for generating definitive clinical evidence and expressed confidence in the program based on prior data and ongoing studies [2] - The company is set to report topline six-month results in early Q4 2026, which could be critical for its future [2] Product Focus - Fractyl Health develops therapies targeting metabolic diseases, including type 2 diabetes and obesity, with its Revita system specifically designed to address duodenal dysfunction [3]

Core Insights - Fractyl Health, Inc. has completed participant randomization in its REMAIN-1 Pivotal Cohort study, which evaluates the effectiveness of Revita for weight maintenance after discontinuation of GLP-1 therapy [1][2][3] - The topline 6-month results from this study are expected to be reported in early Q4 2026, with a potential FDA marketing application submission anticipated in late Q4 2026 [1][7] - The company has reiterated its cash runway guidance, indicating sufficient funds to support operations through early 2027, beyond the pivotal data readout [1][5] Study Design and Objectives - The REMAIN-1 Pivotal Cohort is a randomized, double-blind, sham-controlled study involving adults with obesity (BMI ≥30 kg/m and ≤45 kg/m) who have lost at least 15% of their total body weight on tirzepatide [3] - Participants are randomized in a 2:1 ratio to receive either Revita or a sham procedure, with co-primary endpoints focusing on weight regain at 6 months and the proportion of participants maintaining a ≥5% weight loss at 12 months [3] Clinical and Regulatory Milestones - Fractyl Health is on track for several key clinical and regulatory milestones in 2026, including FDA feedback on the De Novo pathway for Revita expected in Q2 2026 [5][7] - The company plans to report 1-year data from the REVEAL-1 Cohort and the REMAIN-1 Midpoint Cohort randomized data in Q2 and Q3 2026, respectively [7] Product Information - Revita is designed to remodel the duodenal lining through a minimally invasive endoscopic procedure, aiming to restore nutrient sensing and signaling disrupted by chronic metabolic diseases [8] - The product has received FDA Breakthrough Device designation for weight maintenance in individuals who discontinue GLP-1 therapies and is currently for investigational use only in the U.S. [8]

Core Insights - Fractyl Health (GUTS) is focused on developing endoscopic procedures aimed at managing metabolic diseases, specifically obesity and diabetes [1] - The company's lead candidate, Revita, is currently undergoing a registrational phase 3 trial, with topline results anticipated in the second half of 2026 [1] Company Overview - Fractyl Health is engaged in the clinical research of innovative treatments for metabolic disorders [1] - The investment strategy involves focusing on clinical-stage biotech stocks, emphasizing both long-term investment ideas and event-driven trading [1] Clinical Development - Revita is the primary product in development, which is expected to play a significant role in the management of metabolic diseases [1] - The ongoing phase 3 trial is a critical step in the regulatory process, with results expected to influence future investment and market strategies [1]

FDA Approvals & Rejections - Intellia Therapeutics has received FDA approval to resume its MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran (nex-z) targeting hereditary transthyretin amyloidosis with polyneuropathy, increasing target enrollment from 50 to 60 patients [2][4] - Outset Medical's next-generation Tablo Hemodialysis System has been granted FDA 510(k) clearance, making it the first dialysis device to meet enhanced cybersecurity standards, with shipping expected to begin in Q2 2026 [6][7] - OKYO Pharma has received positive feedback from the FDA for its Phase 2b/3 trial design for Urcosimod, a candidate for neuropathic corneal pain, with plans to start the trial in the first half of 2026 [8][9] - REGENXBIO has faced clinical holds on its RGX-111 and RGX-121 gene therapy programs due to a case of CNS tumor in a child treated with RGX-111, although no similar findings were reported in other patients [10][11] - Almirall has received NMPA approval for Seysara in China for treating moderate-to-severe acne vulgaris, expanding its dermatology portfolio in the region [12][13] Clinical Trials - Breakthroughs - Aprea Therapeutics reported early clinical activity for APR-1051 in endometrial cancer, achieving a 50% reduction in target lesion size in a patient with PPP2R1A-mutated uterine serous carcinoma [19][21] - Fractyl Health's Revita demonstrated positive results in weight maintenance after GLP-1 drug discontinuation, showing a 4.5% weight regain compared to 7.5% in the sham group [22][24] - Ascletis Pharma announced positive Phase 3 results for Denifanstat in moderate-to-severe acne vulgaris, focusing on long-term safety in a trial with 240 patients [25][26] - GRI Bio reported new gene expression data from its Phase 2a study of GRI-0621 in idiopathic pulmonary fibrosis, showing significant improvements in lung injury and fibrosis progression [27][28] - Cardiff Oncology announced encouraging results from its Phase 2 trial of Onvansertib in RAS-mutated metastatic colorectal cancer, with a well-tolerated regimen and plans to advance to a registrational program [31][32] - Genentech's CT-388 Phase 2 trial for obesity showed a significant placebo-adjusted weight loss of 22.5% at 48 weeks, with a high percentage of participants achieving significant weight loss [34][36] - Sarepta Therapeutics reported positive three-year results from its EMBARK study for ELEVIDYS in Duchenne muscular dystrophy, showing significant slowing of disease progression in treated patients [38][41] Deals - YD Bio Limited has signed a letter of intent to acquire Safe Save Medical for approximately $26.87 million, aiming to enhance its capabilities in advanced cellular therapeutics [14][15][17]

Core Viewpoint - Fractyl Health Inc. experienced a significant decline in stock price following a potential shift in its regulatory strategy for its lead product, Revita, which is designed to address chronic metabolic diseases [1][8]. Product Overview - Revita is a minimally invasive endoscopic procedure aimed at remodeling the duodenal lining to restore nutrient sensing and signaling disrupted by chronic metabolic disease [2]. - The product has received FDA Breakthrough Device designation for weight maintenance in patients who stop GLP-1 therapies [2]. Regulatory Strategy - The company is seeking FDA feedback on reclassifying Revita under the De Novo pathway instead of the Premarket Approval (PMA) process, which may allow for a more efficient regulatory review [3]. - Feedback from the FDA regarding the De Novo pathway is anticipated in the second quarter of 2026 [4]. Clinical Trial Results - In a six-month randomized study, Revita-treated patients showed a 4.5% weight regain compared to 7.5% in the sham group, indicating a significant reduction in expected weight regain after GLP-1 therapy discontinuation [5]. - An exploratory analysis indicated that patients with above-median weight loss during GLP-1 run-in experienced a 4.2% weight regain versus 13.3% in the sham group, reflecting a 70% relative reduction in post-GLP-1 weight regain [6]. Metabolic Improvements - Revita-treated patients exhibited improvements in cardiometabolic lipid parameters, including a 15.5 mg/dL increase in HDL cholesterol and a reduction in triglyceride-to-HDL ratio, suggesting enhanced metabolic regulation [7]. - Patient-reported outcomes indicated a significant reduction in sweet-food cravings in the Revita group compared to the sham group [7]. Safety Profile - The safety and tolerability of Revita remained favorable over six months, with no serious adverse events related to the device or procedure, and no study discontinuations due to adverse events [8].

Core Viewpoint - Fractyl Health is conducting a conference call to discuss the 6-month REMAIN-1 Midpoint Cohort results, with a focus on the company's developments and future outlook [1][2]. Group 1: Company Overview - The conference is led by Lara Smith-Weber, the Chief Financial Officer, and features Dr. Harith Rajagopalan, the Co-Founder and CEO of Fractyl Health [1][2]. - A press release detailing the topics for discussion has been issued and is available on the company's website under the Investors tab [2]. Group 2: Forward-Looking Statements - The company will make forward-looking statements during the call, which involve risks and uncertainties that could lead to actual results differing from these statements [3]. - A comprehensive list of risk factors is provided in the company's SEC filings, including the quarterly report Form 10-Q filed on November 12, 2025 [3].